Novartis: Stifel still on hold
(CercleFinance.com) - Stifel maintains its Hold rating on Novartis shares, with an unchanged target price of 106 CHF.
This morning, the laboratory reported that it had received accelerated approval from the FDA for Fabhalta (formerly iptacopan) in Nephropathy.
Our estimate is that only around 10-15% of IgAN patients would be eligible for the drug, the analyst points out.
We remain very optimistic about the drug's potential across its range of indications, and see peak sales of over $3bn from 2029 onwards, the broker concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
This morning, the laboratory reported that it had received accelerated approval from the FDA for Fabhalta (formerly iptacopan) in Nephropathy.
Our estimate is that only around 10-15% of IgAN patients would be eligible for the drug, the analyst points out.
We remain very optimistic about the drug's potential across its range of indications, and see peak sales of over $3bn from 2029 onwards, the broker concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.